On 5 March 2022, the China Liver Health led an expert seminar on the diagnosis of hepatitis D virus infection in Beijing. Nearly 20 clinical hepatology and testing experts attended on-site or online to exchange information on the current status of the development and approval of hepatitis D laboratory diagnostic reagents, offer advice and suggestions on the development and implementation of hepatitis D virus testing, and promote the standardization and consistency of hepatitis D testing in China. Gilead (Shanghai) Pharmaceutical Technology Co., Ltd. and Shanghai ISA Medical Technology Co., Ltd. provided public welfare support.
Hepatitis D ("Hepatitis D") is one of the five common types of viral hepatitis, an infectious disease caused by hepatitis D virus (HDV) with inflammation and necrosis of liver cells as the main manifestation. It is more likely to develop into cirrhosis, liver failure and liver cancer than HBV infection alone, and its harmful effects cannot be ignored. However, the detection of hepatitis D in China is still in its infancy, and various diagnostic reagents are of different quality, which is not conducive to the normal development of hepatitis D detection and treatment. Professor Wei Lai, Vice President of Tsinghua Changgeng Hospital in Beijing and Vice President of the China Liver Health, said that it is necessary to exchange and learn from a series of expert seminars on the diagnosis of hepatitis D virus infection, and to form expert opinions on the laboratory diagnosis of hepatitis D and on the use of HDV testing reagents in the clinical diagnosis of HDV. To improve the diagnosis of hepatitis D in China. Professor Wei Lai invited experts to participate in a 5-year follow-up study of hepatitis D led by the China Union Liver Health Promotion Centre and supported by Gilead. In the product introduction session, representatives from five hepatitis D diagnostic reagent manufacturers, including Wantai Bio, Soling Diagnostics, Jena Germany, Shenzhen Taco and Roche Diagnostics, introduced their respective hepatitis D testing technologies and products. During the academic seminar, experts from Peking University Hospital Department, World Health Organization Representative Office in China and renowned medical institutions across China, Academician Zhuang Hui, Professor Cui Fuqiang, Professor Chen Xiaohua, Dr Chen Zhongdan, Dr Chi Xiumei, Professor Jia Jidong, Professor Li Jie, Professor Mao Qing, Professor Nan Yuemin, Professor Niu Junqi, Professor Pan Shiyang, Professor Rao Huiyin, Professor Wei Lai, Professor Wu Chao, Professor Xu Xiaoyuan, Professor Zhang Fujie Professors, who spoke live or online, shared their experience in hepatitis D virus testing and made enquiries and comments on the technology and products of various manufacturers. Academician Zhuang Hui concluded by pointing out that there are an estimated 2 million cases of hepatitis D infection in China, and there is a prospect of carrying out hepatitis D testing. However, the current pre-studies and clinical studies by various reagent companies are not sufficient for approval by the Drug Administration. It is recommended that epidemiological studies be conducted using the current reagents to investigate the proportion of overlapping infections of hepatitis D combined with hepatitis B and C. |
关注官方微信 
